

Press Room

- * TOP STORY
- PRESS RELEASE ARCHIVES
- FACT SHEETS
- SCIENCE WRITER'S GUIDES
- MEDIA DOWNLOADS LIBRARY
- MEDIA CONTACTS
- ABOUT TAKEDA
- COMPLETE PRESCRIBING INFORMATION

Download PDF





Top Story

<u>ACTOS®</u> (pioglitazone HCI) To Be Studied In New Trial Investigating Its Effects On Atherosclerosis In Patients With Type 2 Diabetes

<u>New Results from the Landmark PROactive Trial Found That ACTOS® (pioglitazone HCl)</u> Reduced the Occurrence of Major Adverse Cardiovascular Events